ArticleCase reports in ophthalmological medicine2025
Birdshot Chorioretinopathy in a Patient on Tocilizumab for the Treatment of Giant Cell Arteritis.
Article in Case reports in ophthalmological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Birdshot chorioretinopathy (BSCR) is a presumed autoimmune disease of the eye affecting mostly middle-aged women and typically associated with the HLA-A29 genetic haplotype. Presenting symptoms include blurred vision, nyctalopia, and floaters. Classic fundus findings are multiple, bilateral, creamy, oval lesions around the optic nerve, mostly nasal and inferior to the disc. Fluorescein/indocyanine angiography, optical coherence topography, and fundus autofluorescence can be used for diagnosis and disease monitoring. Here, we present a case of a patient with giant cell arteritis (GCA) on tocilizumab who presented with asymptomatic BSCR lesions in both eyes. Both GCA and BSCR have T cell lymphocyte-mediated inflammation and are treated with corticosteroids. In our case, the patient was on a steroid-sparing agent, which may have suppressed symptoms of BSCR. We found no other cases of a patient having both GCA and BSCR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.